• In late February 2026, Arcus Biosciences reported full-year 2025 results showing revenue of US$247 million versus US$258 million a year earlier, with net loss widening to US$353 million and basic loss per share from continuing operations of US$3.29.
• On the same day, Arcus unveiled updated clinical and pipeline data for its HIF-2α inhibitor casdatifan in kidney cancer, highlighting prolonged progression-free survival, higher response rates, and biomarker correlations that support a push toward tyrosine kinase inhibitor–free frontline treatment regimens.
• We’ll now examine how casdatifan’s kidney cancer data and Arcus’s push toward TKI-free frontline regimens influence the company’s investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Arcus Biosciences Investment Narrative Recap

To own Arcus, you need to believe casdatifan can convert its kidney cancer profile into a meaningful, differentiated franchise while the company manages continued losses and funding needs. The latest data strengthen the scientific story, but the widening 2025 net loss and new at the market equity program keep financing and dilution as the most immediate risk. Near term, the most important catalyst remains upcoming casdatifan data and progress toward pivotal trials rather than the backward looking 2025 revenue trend.

The most relevant update here is Arcus’s plan to start a Phase 3 trial of casdatifan in a tyrosine kinase inhibitor free first line metastatic kidney cancer regimen by the end of 2026. This ties the new efficacy and biomarker data directly to a registrational path, making future readouts from ARC 20 and PEAK 1 key milestones that could reshape how investors view the balance between Arcus’s growing clinical ambition and its need to fund a larger development footprint.

Yet despite the stronger casdatifan story, investors should also be aware that continued net losses, rising R&D spend and fresh equity capacity could...

Arcus Biosciences' narrative projects $327.1 million revenue and $52.5 million earnings by 2028. This requires 7.7% yearly revenue growth and a $350.5 million earnings increase from $-298.0 million today.

Uncover how Arcus Biosciences' forecasts yield a $32.30 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Before this update, the most cautious analysts were assuming revenue could shrink about 5 percent a year with no profits in three years, so if you are worried about funding risk and partnership dependence, this new data may eventually shift those expectations or harden them, depending on how you interpret Arcus’s bigger casdatifan bet.

Explore 4 other fair value estimates on Arcus Biosciences - why the stock might be worth over 8x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arcus Biosciences research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Arcus Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcus Biosciences' overall financial health at a glance.

No Opportunity In Arcus Biosciences?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.